title: Targeted therapies for Hodgkin lymphoma: results of recent trials.
abstract: Many patients with Hodgkin lymphoma (HL) can be cured with standard chemotherapy with high long term survival rates1). Considering the increased risks of various toxicities following therapy, options are evolving towards avoidance of radiation and reduction of therapy duration, with results similar to those currently achieved with improved quality of life2, 3). However, 20-30% of patients still develop recurrence during or following initial therapy, depending upon what chemotherapy regimen is administered4). Investigators have recently described new agents that have produced significant responses in this latter group of patients. In this report, we describe some of these studies, with an emphasis on response and tolerability.
authors: Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center.
authors: Vishwanath
authors: V
authors: Sathyanarayanan
authors: Fredrick
authors: F
authors: Hagemeister
mesh_terms: D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy; D017730:Ki-1 Antigen / Q000276:immunology; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000079963:Brentuximab Vedotin